Centessa (CNTA) Form 4: 40K share option exercise and sale

Centessa Pharmaceuticals plc (CNTA) reported an insider equity transaction by its Chief Technology & Quality Officer.

Rhea-AI Filing Summary

Centessa Pharmaceuticals plc (CNTA) reported an insider equity transaction by its Chief Technology & Quality Officer. On 11/17/2025, the officer exercised a share option covering 40,000 Ordinary Shares at an exercise price of $9.42 per share and, on the same date, sold 40,000 Ordinary Shares at a price of $28 per share under a Rule 10b5-1 trading plan adopted on September 14, 2024. After these transactions, the officer directly owned 121,503 Ordinary Shares and held 360,338 derivative securities (share options) beneficially.

Insider Trade Summary

Exercise and Sale: 40,000 shares ($743K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Bush Tia L

Role Chief Technology & Quality Ofc

Sold 40,000 shs ($1.12M)

Approx. gross sale proceeds $1.12M

Approx. exercise cost $377K

Approx. pre-tax spread $743K

Type	Security	Shares	Price	Value
Exercise	Share Option (right to buy)	40,000	$0.00	$0.00
Exercise	Ordinary Shares	40,000	$9.42	$377K
Sale	Ordinary Shares	40,000	$28.00	$1.12M

Holdings After Transaction: Share Option (right to buy) — 360,338 contracts (Direct); Ordinary Shares — 121,503 shares (Direct)

Footnotes (3)

1. F1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
2. F2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 14, 2024.
3. F3. 25% of the shares subject to such option shall vest and become exercisable on May 20, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Centessa Pharmaceuticals (CNTA) report in this Form 4?

The Chief Technology & Quality Officer of Centessa Pharmaceuticals plc reported exercising an option for 40,000 Ordinary Shares and selling 40,000 Ordinary Shares on 11/17/2025.

At what prices were the Centessa (CNTA) shares exercised and sold?

The officer exercised a share option at an exercise price of $9.42 per Ordinary Share and sold Ordinary Shares at a price of $28 per share.

How many Centessa (CNTA) shares does the reporting person own after the Form 4 transaction?

Following the reported transactions, the officer directly owned 121,503 Ordinary Shares of Centessa Pharmaceuticals plc.

How many derivative securities does the Centessa (CNTA) insider hold after this Form 4 event?

After the transaction, the officer beneficially owned 360,338 derivative securities, consisting of share options over Centessa Ordinary Shares.

Was the Centessa (CNTA) share sale made under a Rule 10b5-1 trading plan?

Yes. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2024.

What are the key vesting terms of the Centessa (CNTA) share option referenced in the Form 4?

The option provided that 25% of the shares vested and became exercisable on May 20, 2022, with the remaining 75% vesting in 36 monthly installments on the first day of each month thereafter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/18/2025 - 04:17 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bush Tia L

(Last) (First) (Middle)

C/O CENTESSA PHARMACEUTICALS PLC

3RD FL., 1 ASHLEY RD, ALTRINCHAM

(Street)

CHESHIRE X0 WA14 2DT

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Centessa Pharmaceuticals plc [ CNTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology & Quality Ofc

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	11/17/2025		M		40,000	A	$9.42	161,503	D
Ordinary Shares(1)	11/17/2025		S(2)		40,000	D	$28	121,503	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	$9.42	11/17/2025		M			40,000	(3)	05/07/2031	Ordinary Shares(1)	40,000	$0	360,338	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 14, 2024.

3. 25% of the shares subject to such option shall vest and become exercisable on May 20, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter.

Remarks:

	/s/ Raphael Deferiere, attorney-in-fact	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.